Impact Of Levalbuterol Versus Albuterol In Kentucky Medicaid Patients,
2010
University of Kentucky
Impact Of Levalbuterol Versus Albuterol In Kentucky Medicaid Patients, Velma Henry
MPA/MPP/MPFM Capstone Projects
Problem:
Asthma is a chronic pulmonary disease that occurs in approximately 10 percent of the population worldwide and is associated with a significant increase in direct medical expenditures. Levalbuterol and racemic albuterol are two short-acting β2-agonists (SABA) prescribed for the treatment of asthma. Racemic albuterol has been used for more than 40 years but is associated with several side effects including tremor. When levalbuterol was approved in 2005 its manufacturer and several studies suggested that using levalbuterol results in better respiratory parameters, fewer hospitalizations, less adverse effects and therefore, lower overall treatment costs and hence less need for β-adrenergic agonist …
